CA3011177A1 - 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives - Google Patents

3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives Download PDF

Info

Publication number
CA3011177A1
CA3011177A1 CA3011177A CA3011177A CA3011177A1 CA 3011177 A1 CA3011177 A1 CA 3011177A1 CA 3011177 A CA3011177 A CA 3011177A CA 3011177 A CA3011177 A CA 3011177A CA 3011177 A1 CA3011177 A1 CA 3011177A1
Authority
CA
Canada
Prior art keywords
methyl
diazaspiro
cis
phenyl
decan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3011177A
Other languages
English (en)
French (fr)
Inventor
Sven Kuhnert
Rene Michael Koenigs
Achim Kless
Anita Wegert
Paul Ratcliffe
Ruth Jostock
Thomas Koch
Klaus Linz
Wolfgang Schroder
Klaus Schiene
Ingo Konetzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of CA3011177A1 publication Critical patent/CA3011177A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3011177A 2016-01-13 2017-01-13 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives Pending CA3011177A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16151013 2016-01-13
EP16151013.6 2016-01-13
PCT/EP2017/025006 WO2017121648A1 (en) 2016-01-13 2017-01-13 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Publications (1)

Publication Number Publication Date
CA3011177A1 true CA3011177A1 (en) 2017-07-20

Family

ID=55129634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3011177A Pending CA3011177A1 (en) 2016-01-13 2017-01-13 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Country Status (28)

Country Link
US (6) US20170197947A1 (https=)
EP (1) EP3402784B1 (https=)
JP (1) JP6893517B2 (https=)
KR (1) KR20180098369A (https=)
CN (1) CN108602777B (https=)
AR (1) AR107360A1 (https=)
AU (1) AU2017206909B2 (https=)
BR (1) BR112018014303B1 (https=)
CA (1) CA3011177A1 (https=)
CL (1) CL2018001912A1 (https=)
CO (1) CO2018008444A2 (https=)
CY (1) CY1122818T1 (https=)
DK (1) DK3402784T3 (https=)
EA (1) EA037481B1 (https=)
EC (1) ECSP18060848A (https=)
ES (1) ES2797904T3 (https=)
HR (1) HRP20200837T1 (https=)
HU (1) HUE049813T2 (https=)
IL (1) IL260491B (https=)
LT (1) LT3402784T (https=)
MX (1) MX378994B (https=)
PE (1) PE20181375A1 (https=)
PL (1) PL3402784T3 (https=)
PT (1) PT3402784T (https=)
RS (1) RS60315B1 (https=)
SI (1) SI3402784T1 (https=)
TW (1) TWI636048B (https=)
WO (1) WO2017121648A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3402782T1 (sl) 2016-01-13 2020-11-30 Grunenthal Gmbh 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
JP6854823B2 (ja) 2016-01-13 2021-04-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 3−(カルボキシメチル)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
EP3722284B1 (en) 2016-01-13 2025-01-22 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PL3402783T3 (pl) 2016-01-13 2020-08-24 Grünenthal GmbH Pochodne 3-(karboksyetylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu
US20170197947A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
JP7446316B2 (ja) 2019-01-11 2024-03-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換ピロリジンアミドiii
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2021016414A1 (en) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
AU2023419893A1 (en) * 2022-12-28 2025-07-03 Gilgamesh Pharmaceuticals, Inc. Synthesis of 2-phenyl-2-amino-cyclohexan-1-one derivatives
US20240400537A1 (en) 2023-04-25 2024-12-05 Gruenenthal Gmbh Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
KR100855204B1 (ko) 2001-04-18 2008-09-01 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
WO2004005293A2 (en) 2002-07-05 2004-01-15 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20080287478A1 (en) 2003-05-23 2008-11-20 Lars Bo Laurenborg Hansen Nociceptin Analogues and Uses Thereof
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JP5079011B2 (ja) 2006-10-19 2012-11-21 エフ.ホフマン−ラ ロシュ アーゲー 糖尿病のための11β−HSD1阻害剤としてのイミダゾロン及びイミダゾリジノン誘導体
JP5490677B2 (ja) 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのorl−1受容体リガンドとしての1,3,8−三置換−1,3,8−トリアザ−スピロ[4.5]デカン−4−オン誘導体
ES2464102T3 (es) * 2008-03-27 2014-05-30 Grünenthal GmbH Derivados de 4-aminociclohexano sustituidos
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物
EP2938341B1 (en) * 2012-12-31 2018-09-05 Sunovion Pharmaceuticals Inc. Heterocyclic compounds and methods of use thereof
WO2015192039A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
US10822385B2 (en) 2016-01-13 2020-11-03 Novo Nordisk A/S EGF(A) analogues with fatty acid substituents
EP3722284B1 (en) 2016-01-13 2025-01-22 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PL3402783T3 (pl) 2016-01-13 2020-08-24 Grünenthal GmbH Pochodne 3-(karboksyetylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu
SI3402782T1 (sl) 2016-01-13 2020-11-30 Grunenthal Gmbh 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
TWI730032B (zh) 2016-01-13 2021-06-11 美商必治妥美雅史谷比公司 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物
JP6854823B2 (ja) 2016-01-13 2021-04-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 3−(カルボキシメチル)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
US20170197947A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives

Also Published As

Publication number Publication date
HUE049813T2 (hu) 2020-10-28
US20210179592A1 (en) 2021-06-17
US10829480B2 (en) 2020-11-10
ES2797904T3 (es) 2020-12-04
BR112018014303B1 (pt) 2023-10-03
US20200002319A1 (en) 2020-01-02
AU2017206909B2 (en) 2020-07-09
EA201891609A1 (ru) 2019-01-31
PL3402784T3 (pl) 2020-09-21
BR112018014303A2 (pt) 2018-12-11
US20200399252A1 (en) 2020-12-24
EA037481B1 (ru) 2021-04-01
PT3402784T (pt) 2020-06-18
AR107360A1 (es) 2018-04-25
EP3402784A1 (en) 2018-11-21
CL2018001912A1 (es) 2018-10-19
ECSP18060848A (es) 2018-08-31
JP2019501939A (ja) 2019-01-24
IL260491B (en) 2021-07-29
DK3402784T3 (da) 2020-05-25
PE20181375A1 (es) 2018-08-28
WO2017121648A1 (en) 2017-07-20
EP3402784B1 (en) 2020-03-11
CN108602777B (zh) 2022-05-03
NZ745188A (en) 2024-05-31
MX2018008644A (es) 2018-11-19
RS60315B1 (sr) 2020-07-31
MX378994B (es) 2025-03-11
US20230174520A1 (en) 2023-06-08
CN108602777A (zh) 2018-09-28
CO2018008444A2 (es) 2018-08-31
JP6893517B2 (ja) 2021-06-23
US20170197947A1 (en) 2017-07-13
SI3402784T1 (sl) 2020-07-31
TW201731822A (zh) 2017-09-16
HRP20200837T1 (hr) 2020-08-07
LT3402784T (lt) 2020-06-10
KR20180098369A (ko) 2018-09-03
TWI636048B (zh) 2018-09-21
AU2017206909A1 (en) 2018-08-30
US20180327392A1 (en) 2018-11-15
CY1122818T1 (el) 2021-05-05

Similar Documents

Publication Publication Date Title
CA3011177A1 (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EP3402782B1 (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EP3402783B1 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EP3402781A1 (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260472B (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260472A1 (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK40035886A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260545A1 (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260545B (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260461A1 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260461B (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260528B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260528A1 (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210921

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20240715

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250715

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226